{"aliases":[{"type":"Synonym","name":"anti-CD125 humanized monoclonal antibody, IgG1-kappa"},{"type":"CodeName","name":"MEDI-563"},{"type":"CodeName","name":"KHK-4563"},{"type":"USBrandName","name":"Fasenra"},{"type":"CodeName","name":"BIW-8405"},{"type":"CASRegistryName","name":"1044511-01-4"}],"definition":{"html":"An afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra), with potential anti-asthmatic activity. Upon administration, benralizumab binds to IL-5Ra and elicits an antibody-directed cell cytotoxicity (ADCC) against IL-5Ra-expressing cells. This induces apoptosis in IL-5Ra-expressing cells and may reduce asthmatic episodes. IL-5Ra, expressed on both eosinophils and basophils, plays a key role in asthma.","text":"An afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra), with potential anti-asthmatic activity. Upon administration, benralizumab binds to IL-5Ra and elicits an antibody-directed cell cytotoxicity (ADCC) against IL-5Ra-expressing cells. This induces apoptosis in IL-5Ra-expressing cells and may reduce asthmatic episodes. IL-5Ra, expressed on both eosinophils and basophils, plays a key role in asthma."},"drugInfoSummaryLink":null,"nciConceptId":"C88594","nciConceptName":"Benralizumab","termId":794137,"name":"benralizumab","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"benralizumab"}